These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28089457)

  • 1. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension.
    Zhao D; Liu H; Dong P; Zhao J
    Int J Cardiol; 2017 Apr; 233():113-117. PubMed ID: 28089457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.
    Pelliccia F; Patti G; Rosano G; Greco C; Gaudio C
    Int J Cardiol; 2014 Nov; 177(1):219-28. PubMed ID: 25499383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials.
    Liu L; Xu B; Ju Y
    Clin Exp Hypertens; 2017; 39(3):257-263. PubMed ID: 28448185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
    Oliveras A; Armario P; Clarà A; Sans-Atxer L; Vázquez S; Pascual J; De la Sierra A
    J Hypertens; 2016 Sep; 34(9):1863-71. PubMed ID: 27327441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone for hypertension.
    Batterink J; Stabler SN; Tejani AM; Fowkes CT
    Cochrane Database Syst Rev; 2010 Aug; (8):CD008169. PubMed ID: 20687095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
    Václavík J; Sedlák R; Plachy M; Navrátil K; Plásek J; Jarkovsky J; Václavík T; Husár R; Kociánová E; Táborsky M
    Hypertension; 2011 Jun; 57(6):1069-75. PubMed ID: 21536989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials.
    Wang C; Xiong B; Huang J
    Heart Lung Circ; 2016 Oct; 25(10):1021-30. PubMed ID: 27118266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis.
    Chen C; Zhu XY; Li D; Lin Q; Zhou K
    Medicine (Baltimore); 2020 Aug; 99(34):e21694. PubMed ID: 32846786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension.
    Zhao D; Liu H; Dong P
    Clin Exp Hypertens; 2019; 41(1):75-79. PubMed ID: 29589977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review of Add-on Pharmacologic Therapy in the Treatment of Resistant Hypertension.
    Tataru AP; Barry AR
    Am J Cardiovasc Drugs; 2017 Aug; 17(4):311-318. PubMed ID: 28349274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.
    Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):50-5. PubMed ID: 23128822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
    Hou J; Xiong W; Cao L; Wen X; Li A
    Clin Ther; 2015 Sep; 37(9):2086-2103.e10. PubMed ID: 26254276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone and doxazosin treatment in patients with resistant hypertension.
    Rodilla E; Costa JA; Pérez-Lahiguera F; Baldó E; González C; Pascual JM
    Rev Esp Cardiol; 2009 Feb; 62(2):158-66. PubMed ID: 19232189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
    Widimský J
    Vnitr Lek; 2015 Dec; 61(12):1067-71. PubMed ID: 26806502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of spironolactone therapy in patients with true resistant hypertension.
    de Souza F; Muxfeldt E; Fiszman R; Salles G
    Hypertension; 2010 Jan; 55(1):147-52. PubMed ID: 19858405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.
    Shlomai G; Sella T; Sharabi Y; Leibowitz A; Grossman E
    Hypertens Res; 2014 Dec; 37(12):1037-41. PubMed ID: 24671013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT).
    Václavík J; Sedlák R; Jarkovský J; Kociánová E; Táborský M
    Medicine (Baltimore); 2014 Dec; 93(27):e162. PubMed ID: 25501057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronotherapy of Hypertension with Angiotensin Receptor Blockers-A Meta-Analysis of Blood Pressure Measured by Ambulatory Blood Pressure Monitoring in Randomized Trials.
    Zhao D; Liu H; Dong P
    Am J Med Sci; 2021 Jan; 361(1):36-42. PubMed ID: 32948291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes.
    Lin M; Heizati M; Wang L; Nurula M; Yang Z; Wang Z; Abudoyreyimu R; Wu Z; Li N
    Blood Press; 2021 Jun; 30(3):145-153. PubMed ID: 33682538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.